TMO Q3 2026 Earnings Analysis
Thermo Fisher reported strong Q3 with $12.14B revenue (+9%), 6% organic growth, and $6.68 adjusted EPS (+15%), raising 2026 guidance on end-market strength.
Key Metrics
Key Takeaways
- Q3 revenue $12.14B (+9%), organic growth 6%, adjusted EPS $6.68 (+15%) on pharma/biotech strength.
- FY guidance raised to $47.7-48.2B revenue (+7-8%), $25.13-25.43 EPS (+10-11%) from operational performance.
- New product launches (Orbitrap Isora, EMPAD G2) and AI clinical research tools drive innovation and market share.
Listen On
Available In
Transcript
// Full episode scriptWelcome to Beta Finch, your AI-powered earnings breakdown! Today we're diving into Thermo Fisher Scientific's third quarter 2026 results — and Jordan, this is a good one.
Oh, it's a good one. Beat and raise, strong end markets, tariff refunds... there's a lot to unpack.
There really is. But before we get into it — quick reminder for everyone listening: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.
Important stuff, let's get into the numbers.
Okay, so headline numbers first. Revenue came in at $12.14 billion, up 9% year-over-year. Adjusted EPS grew 15% to $6.68 per share. And adjusted operating margin expanded 120 basis points to 24.5%.
And here's the thing — this wasn't just "in line" or a small beat. CFO Jim Meyer said Q3 revenue came in more than $200 million ahead of their prior guidance, and EPS beat by $0.26. That's a real beat.
Right, and there's an interesting wrinkle in that EPS beat. $0.08 came from genuinely strong operational execution, $0.03 from foreign exchange, but $0.15 — more than half — came from tariff refunds that got recovered in the quarter.
Yeah, that tariff refund piece is worth sitting with for a second. Management said they received approvals on the vast majority of their total potential refund claims this quarter. That added about $60 million to adjusted operating income — roughly 50 basis points of margin. But here's what I liked: they didn't just drop it straight to the bottom line. They reinvested a chunk of it into AI deployment, capacity scale-up in Pharma Services, and employee investments.
Which tells you management is thinking medium-term, not just trying to make this quarter look good.
Exactly. It's a one-time windfall, and they treated it like one — put it to work rather than just banking it.
Let's talk end markets, because this is really the heart of the story. Pharma and biotech — their biggest and most important market — grew high single digits, led by Pharma Services and the research and safety channel. Academic and government was flat, which was expected. Industrial and applied grew high single digits, driven by electron microscopy and semiconductor demand. And diagnostics and healthcare grew low single digits.
The pharma and biotech story is the one analysts kept circling back to in the Q&A. CEO Marc Casper talked about this almost like a staged recovery — first you saw clinical trial authorizations pick up, then lab-based research activity in biotech, and now they're expecting the high-end reagents business to be the next leg of that recovery over the next couple of quarters.
It's basically a domino effect working through the biotech funding recovery.
And geographically, Asia Pacific — including China — grew low double digits. That's notable. China's been a wildcard for a lot of life sciences companies, and Thermo's seeing real strength there.
Now let's talk strategy, because there were some real moves this quarter. The Clario acquisition — that's the clinical research technology business — integration is going smoothly, and management's already talking about revenue synergies building.
They also hit the one-year anniversary of the filtration and separation business acquisition, which they said strengthened their bioproduction capabilities. And on the flip side, they completed the divestiture of the microbiology business — which actually dragged reported revenue down about 1 point, but it's part of streamlining the portfolio toward higher-growth areas.
Classic portfolio pruning — add the high-growth stuff, shed the slower-growth stuff.
And AI came up constantly on this call. Not just as a buzzword — they gave concrete examples. AI-enabled software on their cryo-electron microscopes is cutting manual setup time by about 90%. They launched an AI clinical research assistant to help with trial site engagement and risk assessment.
One of the more interesting exchanges in the Q&A was analysts pushing Casper on whether AI could actually lift the long-term growth algorithm beyond their stated 7% organic growth target. His answer was basically: 7% isn't a ceiling, it's a milestone they haven't hit in a while and want to get back to first.
He compared it to COVID vaccines and GLP-1 drugs — saying when medicine makes a big enough difference in human health, the market response is almost unprecedented in scale. If AI accelerates more breakthroughs like that, it's a tailwind for everybody in this ecosystem, Thermo included.
Now, guidance — they raised it. New full-year revenue range of $47.7 to $48.2 billion, with organic growth guidance bumped up to 4% for the year. Adjusted EPS guidance raised to $25.13-$25.43, representing 10-11% growth.
And free cash flow guidance went up too, now $7 to $7.5 billion for the year. One thing that stood out to me: an analyst asked why Q4 organic growth guidance is "only" 4% when Q3 just printed 6%. Jim Meyer's answer was pretty clean — a lot of Pharma Services momentum got pulled forward into Q3 on customer activity timing, but the underlying business momentum is still strong heading into Q4.
So not a red flag, more of a timing shuffle.
Right. And zooming out, when asked about 2027, Casper was candid that he's not going to pin an exact quarter, but the trajectory is pointing toward Thermo working back toward that 7% long-term organic growth target as markets normalize.
So what's the big picture for investors here? Strong quarter, raised guidance, real recovery momentum in pharma and biotech, smart capital deployment with Clario and the filtration business, and AI showing up as a genuine product differentiator rather than just talk.
And before we wrap — important reminder: everything discussed is AI-generated analysis for educational purposes. Past performance doesn't guarantee future results. Please do your own due diligence.
Well said. Looking ahead, Thermo's next big checkpoint is February 2nd, when they report full-year results and give initial 2027 guidance — that'll be a key moment to see if this recovery narrative keeps building.
Definitely one to watch. Thanks for tuning in to Beta Finch!
We'll see you next time!